November 9th 2018
Good run continues for Imugene with $1.85M R&D tax incentive
October 3rd 2017
Immuno-oncology: a new horizon in the fight against cancer
September 26th 2017
Is IMU on the path to a viable cure for cancer?
June 16th 2017
Merger and acquisition activity heightens in healthcare sector
May 17th 2017
Will Imugene’s expertise in immunotherapies result in an AstraZeneca type rerating?
April 7th 2017
Support from leading institutional investors augurs well for Imugene
March 30th 2017
How Imugene is tackling gastric cancer
Connect with us